Drug Profile
Malaria vaccine - GenVec/Naval Medical Research Center
Alternative Names: DNA-Ad; NMRC-M3V-Ad-PfCA vaccineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GenVec; Naval Medical Research Center
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 15 Sep 2015 No recent reports on development identified - Phase-I/II for Malaria (Prevention, In volunteers) in USA (Parenteral)
- 26 Mar 2012 GenVec receives grant from NIAID of the NIH for malaria vaccine development in Malaria